IL17A and cancer: The levels of other ligands from the IL-17 family (E/F) and IL-17RB receptors, along with neutrophil and mast cell infiltration, were significantly reduced in cancer compared to benign lesions, unlike the IL17RC ligand, which together with CD3+ cell infiltration was more highly expressed in CRC than in polyps [217].